HOUSTON, Aug. 14, 2026
Moleculin Biotech is advancing its lead cancer therapy Annamycin through the pivotal Phase 2/3 MIRACLE trial in adults with relapsed or refractory acute myeloid leukemia (AML) following positive preliminary efficacy findings from the study. The interim analysis of the first 45 patients enrolled in Part A showed that both Annamycin treatment groups achieved complete remission (CR) rates at least three times higher than the control arm, strengthening the clinical rationale for continued development. The 190 mg/m² Annamycin plus cytarabine group achieved a 43% CR rate, while the 230 mg/m² group achieved a 36% CR rate, compared with 12% for the cytarabine control arm. Composite complete remission rates were also higher in both Annamycin groups, reaching 50% and 57%, respectively, versus 29% for control. The findings provide an important clinical signal as Moleculin continues enrollment toward the planned 90-patient milestone in September 2026.
MIRACLE Trial Advances Toward Key Efficacy Readout
The MIRACLE trial is evaluating Annamycin in combination with cytarabine, known as AnnAraC, using an adaptive Phase 2/3 design intended to identify the optimal dose for further development in relapsed or refractory AML. More than 80% of the planned 90 patients had been enrolled as of the interim analysis, and Moleculin expects to complete Part A enrollment in September 2026. Following completion of the 90-patient cohort, the company expects an unblinded efficacy readout between December 2026 and February 2027, which will help guide dose selection and the planned initiation of Part B during the first half of 2027. The continued progress of the trial is particularly significant because relapsed or refractory AML remains a difficult-to-treat disease with substantial unmet medical need. Moleculin is therefore using the emerging clinical data to determine the most appropriate Annamycin dose and advance the program toward potentially later-stage development and regulatory discussions.
Annamycin Clinical Profile Highlights Cardiac Safety
Alongside the remission findings, cardiac safety remains a major focus of Annamycin’s development program. Moleculin reported that the MIRACLE trial continues to show an absence of detectable cardiotoxicity, including after cumulative exposure levels that exceed conventional anthracycline limits. This characteristic is important because cardiotoxicity is a well-recognized limitation associated with conventional anthracycline chemotherapy. Data presented at the 2026 ASCO Annual Meeting further supported the company’s assessment of Annamycin’s differentiated cardiac safety profile. Moleculin also reported strong investigator interest in the MIRACLE program, with physicians citing the potential combination of efficacy, transplant-bridging potential and cardiac safety as factors supporting continued evaluation. The company is also planning additional clinical development activities, including potential studies in third-line relapsed/refractory AML, pediatric AML and other cancer settings, while maintaining Annamycin as its primary clinical development focus.
Financial Position Supports Continued Clinical Development
Moleculin reported that it had approximately $7.3 million in cash and cash equivalents as of June 30, 2026, with an additional $9.3 million raised after the quarter ended, which management expects to support planned operations into the first quarter of 2027. Research and development expenses increased to $5.5 million during the second quarter, primarily reflecting higher spending associated with the MIRACLE clinical trial and supporting nonclinical studies, while general and administrative expenses remained approximately $2.1 million. The company continues to support development activities for WP1066 and other pipeline programs, but the central focus remains Annamycin and the MIRACLE trial. With Part A enrollment approaching completion, the upcoming 90-patient efficacy readout and subsequent dose-selection decision represent the next major milestones for Moleculin’s AML program
Source:Moleculin Biotech,, press relese



